NCT02743637View on ClinicalTrials.gov

A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions
Advanced MalignancyAdvanced Solid TumorsNeoplasmMetastasis
Interventions
DRUG

SDX-7320

SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.

Trial Locations (3)

37203

Sarah Cannon Research Institute, Nashville

85258

HonorHealth Research Institute, Scottsdale

90048

Cedars Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

SynDevRx, Inc.

INDUSTRY

NCT02743637 - A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors | Biotech Hunter | Biotech Hunter